3D-written model improves understanding of cancer

Purdue researchers, led by Luis Solorio, have developed a 3D-written model that created a lifelike cancer environment to better predict how drugs interact with metastasized cells. Findings were published in Advanced Materials.

Solorio, an assistant professor of biomedical engineering, and a team of researchers proposed 3D writing instead of 3D printing in developing a more lifelike cancer environment. The 3D jet-writer produces polymer microtissues as they are shaped in the body, but on a smaller scale, to print an environment with pores large enough for cells to enter the polymer structure. The structure then forms a scaffold that facilitates cell activity as in the body.

So far, researchers have used the 3D jet-writer device to create a structure capable of drawing in cancer cells in mice where cancer would not normally develop, showing the device's ability to create a cancer environment.

"Ideally, we could use our system as an unbiased drug screening platform where we could screen thousands of compounds, hopefully get data within a week, and get it back to a clinician so that it's all within a relevant time frame," Solorio said.

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup